JPH04299998A - Halitosis bacterium-examining chemical - Google Patents

Halitosis bacterium-examining chemical

Info

Publication number
JPH04299998A
JPH04299998A JP3089674A JP8967491A JPH04299998A JP H04299998 A JPH04299998 A JP H04299998A JP 3089674 A JP3089674 A JP 3089674A JP 8967491 A JP8967491 A JP 8967491A JP H04299998 A JPH04299998 A JP H04299998A
Authority
JP
Japan
Prior art keywords
halitosis
cysteine
bacteria
group
methionine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3089674A
Other languages
Japanese (ja)
Inventor
Masao Ishikawa
正夫 石川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lion Corp
Original Assignee
Lion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lion Corp filed Critical Lion Corp
Priority to JP3089674A priority Critical patent/JPH04299998A/en
Publication of JPH04299998A publication Critical patent/JPH04299998A/en
Pending legal-status Critical Current

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

PURPOSE:To obtain a halitosis causative-examining chemical consisting of S group-substituted derivative of L-cysteine or L-methionine, and capable of simply and specifically detecting a halitosis bacterium such as Fusobacterium nucleatum or halitosis in high sensitivity. CONSTITUTION:The objective halitosis causative-examining chemical consisting of a L-cysteine or L-methionine derivative (salt) expressed by formula I or formula II (Y is functional group capable of measuring an amount of Y-SH produced by metabolism of halitosis bacteria by a visible light, ultraviolet ray, infrared ray or fluorescence). The compound expressed by formula I includes e.g. S-(p-nitrophenyl)-L-cysteine.

Description

【発明の詳細な説明】[Detailed description of the invention]

【0001】0001

【産業上の利用分野】本発明は、口臭の検査等に使用さ
れる口臭菌検査薬に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a drug for testing bad breath bacteria, which is used to test for bad breath.

【0002】0002

【従来の技術及び発明が解決しようとする課題】従来、
口臭を測定する方法としては、口臭を直接又は間接的に
測定する方法、口臭代替物質を測定する方法、口臭菌と
歯周病原性細菌との関連性から歯周病原性関連物質を測
定する方法が知られており、例えば下記(1)〜(3)
に示す方法が提案されている。 (1)口臭を直接官能的に或いはガスクロマトグラフィ
等の機器を用いて測定し評価する方法(梅津健樹,日歯
周誌,18,1−22,(1976))、口臭センサー
(ガス検知素子)で口臭を測定し評価する方法(特開昭
58−208651号公報)。 (2)口臭菌代替物質として唾液中のSH化合物(還元
物質)や亜硝酸イオンを測定する方法(特開昭57−1
48252,同62−115364,同62−1153
65,同59−33826,同62−294943号公
報)。 (3)バクテロイデス・ジンジバリスに対するモノクロ
ナール抗体を用いて歯周病の病巣におけるバクテロイデ
ス・ジンジバリスの動態を調べる方法(特開昭60−7
3463号公報)、歯周病原性細菌抗原を測定する方法
(特開昭61−162753号公報)、特定の基質を用
いて歯周病原性細菌が産生するアミノペプチターゼ様酵
素活性を特異的に測定する歯周疾患検査薬(特開昭63
−36800号公報)。
[Prior art and problems to be solved by the invention] Conventionally,
Methods for measuring halitosis include methods that directly or indirectly measure halitosis, methods that measure halitosis substitute substances, and methods that measure periodontal pathogenic substances based on the relationship between halitosis bacteria and periodontal pathogenic bacteria. are known, for example, the following (1) to (3)
The following method has been proposed. (1) Method of measuring and evaluating bad breath directly sensually or using equipment such as gas chromatography (Kenki Umezu, Japanese Periodontal Journal, 18, 1-22, (1976)), bad breath sensor (gas detection element) A method for measuring and evaluating bad breath (Japanese Unexamined Patent Publication No. 58-208651). (2) Method for measuring SH compounds (reducing substances) and nitrite ions in saliva as a substitute for halitosis bacteria (JP-A-57-1
48252, 62-115364, 62-1153
65, No. 59-33826, No. 62-294943). (3) Method for investigating the dynamics of Bacteroides gingivalis in lesions of periodontal disease using monoclonal antibodies against Bacteroides gingivalis (Japanese Patent Application Laid-Open No. 60-7
3463), a method for measuring periodontopathogenic bacterial antigens (JP-A-61-162753), and a method for specifically measuring aminopeptidase-like enzyme activity produced by periodontal pathogenic bacteria using a specific substrate. Periodontal disease test drug to measure
-36800).

【0003】しかしながら、口臭を測定する方法はその
ための設備が必要となり、口臭センサーを用いる方法は
口臭菌以外の成分とも反応するので特異性に問題があり
、口臭代替物質を測定する方法は測定精度において改善
すべき点があり、歯周疾患検査薬は感度が十分ではない
等の問題を有する。
[0003] However, methods for measuring halitosis require equipment, methods using halitosis sensors have problems with specificity as they react with components other than halitosis bacteria, and methods for measuring halitosis substitutes have poor measurement accuracy. There are issues that need to be improved, and periodontal disease testing agents have problems such as insufficient sensitivity.

【0004】0004

【課題を解決するための手段及び作用】本発明者は、上
記従来技術とは異なる新しい口臭菌検査方法につき鋭意
検討を行った。即ち、L−システイン,L−メチオニン
等の口臭原因基質の含硫アミノ酸がフゾバクテリウム,
ポリフォモナス(バクテロイデス),バイオネーラ,ス
ピロヘータ(トレポネーマ)等の口腔内細菌の酵素反応
により代謝されて悪臭成分のH2S,CH3SHとなる
(歯科基礎抄録集29,199(1987)参照)こと
に着目し、更に検討を進めた結果、上記含硫アミノ酸の
誘導体(下記式(1)又は(2)のL−システイン又は
L−メチオニン(ホモシステイン)のS基置換誘導体又
はその塩)を用いることにより、口臭菌の測定が可能に
なり、口臭を容易に検査することができることを知見し
た。
[Means for Solving the Problems and Effects] The present inventor has conducted intensive studies on a new method for testing bad breath bacteria, which is different from the above-mentioned conventional techniques. That is, sulfur-containing amino acids such as L-cysteine and L-methionine, which are substrates that cause bad breath, are
Focusing on the fact that it is metabolized by the enzymatic reaction of oral bacteria such as Polyphomonas (Bacteroides), Bionella, and Spirochete (Treponema) to become malodorous components H2S and CH3SH (see Dentistry Abstracts 29, 199 (1987)). As a result of further investigation, it was found that by using the above-mentioned sulfur-containing amino acid derivative (S-substituted derivative of L-cysteine or L-methionine (homocysteine) of formula (1) or (2) below, or a salt thereof), bad breath can be reduced. It has become possible to measure bacteria, and it has been discovered that bad breath can be easily tested.

【0005】         Y−S−CH2−CH(NH)−CO
OH          …(1)        Y
−S−CH2−CH2−CH(NH2)−COOH  
…(2)(但し、Yは口臭菌により代謝されて生成する
Y−SHの量を可視部、紫外部、赤外部又は螢光で測定
可能にする官能基を示す。)ここで、上記L−システイ
ン又はL−メチオニンの誘導体を用いることにより口臭
菌が測定され、口臭の検査が可能になる理由は下記のよ
うに推定される。
YS-CH2-CH(NH)-CO
OH…(1) Y
-S-CH2-CH2-CH(NH2)-COOH
...(2) (However, Y represents a functional group that makes it possible to measure the amount of Y-SH produced by metabolism by halitosis bacteria in the visible region, ultraviolet region, infrared region, or fluorescence.) Here, the above L - The reason why halitosis bacteria can be measured and halitosis testing becomes possible by using derivatives of cysteine or L-methionine is presumed as follows.

【0006】即ち、下記反応式Aに示すように、代謝酵
素のL−システインデスルフィドラーゼ,メチオニンγ
−リアーゼにより、口臭原因菌の基質であるL−システ
イン,L−メチオニンが代謝するときに悪臭成分(硫化
水素H2S,メチルメルカプタンCH3SH)が産生さ
れると考えられるが、上記含硫アミノ酸の代わりに例え
ば下記反応式Bに示すような含硫アミノ酸誘導体を用い
ることにより、上記と同様の代謝(酵素)によってα−
ケト酸又はp−ニトロフェニルメルカプタン(黄色)が
産生し、これを測定することにより口臭菌又は口臭の測
定が可能になるものである。
That is, as shown in reaction formula A below, the metabolic enzyme L-cysteine desulfidolase, methionine γ
-It is thought that malodorous components (hydrogen sulfide H2S, methyl mercaptan CH3SH) are produced when lyase metabolizes L-cysteine and L-methionine, which are the substrates of bad breath-causing bacteria, but instead of the sulfur-containing amino acids mentioned above, For example, by using a sulfur-containing amino acid derivative as shown in reaction formula B below, α-
Keto acid or p-nitrophenyl mercaptan (yellow) is produced, and by measuring this, it is possible to measure halitosis bacteria or bad breath.

【0007】[0007]

【化1】[Chemical formula 1]

【0008】従って、上記(1)式又は(2)式のL−
システイン又はL−メチオニンの誘導体又はその塩を口
臭菌検査薬として用いることにより、口臭菌、特にフゾ
バクテリウム・ヌクリータム、フゾバクテリウム・ネク
ロフォルム(necrophorm)、ポリフォモナス
・ジンジバリス、バクテロイデス・デンティコーラ、バ
イオネーラ・ディスパー、バイオネーラ・パルブラ、ト
レポネーマ・デンティコーラなどの検出或いは口臭検査
が簡便、高感度、特異的になされ、また上記L−システ
イン又はL−メチオニンの誘導体又はその塩を選定する
ことにより、可視部の発色で直接視覚的に口臭を認知す
ることも可能になるものである。
[0008] Therefore, L- in the above formula (1) or (2)
By using cysteine or L-methionine derivatives or their salts as halitosis bacteria testing agents, halitosis bacteria, particularly Fusobacterium nucleum, Fusobacterium necrophorm, Polyphomonas gingivalis, Bacteroides denticola, Bionella disper, Bionella・Detection of Parvula, Treponema denticola, etc. or bad breath test can be easily, highly sensitive, and specific, and by selecting the above-mentioned L-cysteine or L-methionine derivatives or their salts, it can be directly detected by color development in the visible part. It also makes it possible to recognize bad breath.

【0009】以下、本発明につき更に詳しく説明すると
、本発明の口臭菌検査薬は口臭の原因菌の基質であるL
−システイン,L−メチオニンの誘導体又はその塩を用
いることにより、L−システイン,L−メチオニンの代
謝時と同様の代謝(酵素)系で口臭菌又は口臭を判定す
るものであリ、該L−システイン,L−メチオニンの誘
導体として下記式(1)又は(2)を用いるものである
[0009] The present invention will be explained in more detail below. The halitosis bacteria testing agent of the present invention uses
- By using derivatives of cysteine, L-methionine, or salts thereof, halitosis bacteria or bad breath can be determined using the same metabolic (enzyme) system as used for the metabolism of L-cysteine and L-methionine. The following formula (1) or (2) is used as a derivative of cysteine or L-methionine.

【0010】         Y−S−CH2−CH(NH2)−C
OOH          …(1)        
Y−S−CH2−CH2−CH(NH2)−COOH 
 …(2)(但し、Yは口臭菌により代謝されて生成す
るY−SHの量を可視部、紫外部、赤外部又は螢光で測
定可能にする官能基を示す。)
Y-S-CH2-CH(NH2)-C
OOH…(1)
Y-S-CH2-CH2-CH(NH2)-COOH
...(2) (However, Y represents a functional group that allows the amount of Y-SH produced by metabolism by halitosis bacteria to be measured using visible light, ultraviolet light, infrared light, or fluorescence.)

【0011】ここで、上
記官能基(発色基)は、上記したように可視部、紫外部
、赤外部、螢光で測定可能な官能基であり、このような
官能基としては、フェニル基、ベンジル基、ベンゾイル
基、プリン基、イミダゾール基、ナフチル基等を骨格と
する基を例示することができ、具体的には、o−又はp
−ニトロフェニル基、o−又はp−ニトロベンジル基、
o−又はp−ニトロベンゾイル基、α−又はβ−ニトロ
ナフチル基、o−又はp−ブロモフェニル基、o−又は
p−ブロモベンジル基、o−又はp−ブロモベンゾイル
基、α−又はβ−ブロモナフチル基、o−又はp−アミ
ノフェニル基、o−又はp−アミノベンジル基、o−又
はp−アミノベンゾイル基、α−又はβ−アミノナフチ
ル基等が挙げられ、更に上記骨格にニトロ基、ブロモ基
、アミノ基を2つ以上含む基、ベンゾチアゾール基等が
挙げられる。
[0011] Here, the above-mentioned functional group (chromogenic group) is a functional group that can be measured in the visible region, ultraviolet region, infrared region, and fluorescence, as described above, and such functional groups include phenyl group, Examples include groups having a benzyl group, benzoyl group, purine group, imidazole group, naphthyl group, etc., and specifically, o- or p-
-nitrophenyl group, o- or p-nitrobenzyl group,
o- or p-nitrobenzoyl group, α- or β-nitronaphthyl group, o- or p-bromophenyl group, o- or p-bromobenzyl group, o- or p-bromobenzoyl group, α- or β- Examples include bromonaphthyl group, o- or p-aminophenyl group, o- or p-aminobenzyl group, o- or p-aminobenzoyl group, α- or β-aminonaphthyl group, and furthermore, a nitro group in the above skeleton. , a bromo group, a group containing two or more amino groups, a benzothiazole group, and the like.

【0012】本発明の検査薬は、種々の形態に調製する
ことができ、例えば水溶液形態等に調製し得るほか、こ
の水溶液の形態のものを瀘紙に含浸・乾燥させたり、ド
ライケミストリーの技術を利用することにより各種試験
紙へ展開したものも含まれる。
The test agent of the present invention can be prepared in various forms, for example, in the form of an aqueous solution, or by impregnating filter paper with this aqueous solution and drying it, or using dry chemistry techniques. This also includes those developed into various test papers by using .

【0013】また、本発明の検査薬は、他の試薬を組み
合わせてキット化することもでき、キット化することに
より定量の精度をより高めることができる。  更に、
本発明の口臭菌検査薬は、フゾバクテリウム・ヌクリー
タム,ポリフォモナス・ジンジバリス,スピロヘータ等
の広範囲の口腔細菌に代謝されるので、歯周病の原因細
菌の検査への応用も可能である。
[0013] Furthermore, the test reagent of the present invention can be made into a kit by combining other reagents, and by making it into a kit, the precision of quantitative determination can be further improved. Furthermore,
The halitosis bacteria test drug of the present invention is metabolized by a wide range of oral bacteria such as Fusobacterium nucleum, Polyphomonas gingivalis, and spirochetes, so it can also be applied to testing for periodontal disease-causing bacteria.

【0014】[0014]

【実施例】次に、実験例を示して本発明の効果を具体的
に説明する。
[Example] Next, the effects of the present invention will be specifically explained with reference to experimental examples.

【0015】[実験例]まず、各種口腔内細菌をGAM
培地中において37℃,48〜72時間の条件で嫌気培
養し、菌濃度を1.0(波長660nmにおける吸光度
)に調整した。次に、1.0mMの表1に示す基質溶液
(pH7.5,0.5Mリン酸緩衝液)2mlと菌液0
.5mlを37℃で30分間反応させた。反応終了後、
生じたα−ケト酸(ピルビン酸又はα−ケト酪酸)を左
右田らの方法(Agric.Biol.Chem.31
,1054−1060(1967))で定量し、下記の
判定基準に従って4段階に判定した。結果を表1に併記
する。 判定基準 −:α−ケト酸を検出できず +:L−システインから産生したα−ケト酸と同レベル
の検出量 ++:L−システインから産生したα−ケト酸の5〜1
0倍レベルの検出量 +++:L−システインから産生したα−ケト酸の20
倍以上の検出量
[Experiment example] First, various oral bacteria were
Anaerobic culture was performed in a medium at 37° C. for 48 to 72 hours, and the bacterial concentration was adjusted to 1.0 (absorbance at a wavelength of 660 nm). Next, add 2 ml of 1.0 mM substrate solution shown in Table 1 (pH 7.5, 0.5 M phosphate buffer) and 0.0 ml of bacterial solution.
.. 5 ml was reacted at 37°C for 30 minutes. After the reaction is complete,
The resulting α-keto acid (pyruvic acid or α-ketobutyric acid) was purified using the method of Soda et al. (Agric. Biol. Chem. 31
, 1054-1060 (1967)) and judged in four stages according to the following criteria. The results are also listed in Table 1. Judgment criteria -: α-keto acid cannot be detected +: Detection amount at the same level as α-keto acid produced from L-cysteine ++: 5 to 1 of α-keto acid produced from L-cysteine
Detection amount +++ at 0 times level: 20% of α-keto acid produced from L-cysteine
Detection amount more than double

【0016】[0016]

【表1】[Table 1]

【0017】表1の結果より、L−システイン及びL−
メチオニンの発色基を有する誘導体は口臭原因菌を容易
に感度よく検出し得ることが認められた。
From the results in Table 1, L-cysteine and L-
It has been found that derivatives having a methionine coloring group can easily and sensitively detect bacteria that cause bad breath.

【0018】以下、実施例を示し、本発明を具体的に説
明するが、本発明は下記の実施例に制限されるものでは
ない。
The present invention will be specifically explained below with reference to Examples, but the present invention is not limited to the following Examples.

【0019】[実施例1]ガスクロマトグラフィを用い
て被験者の呼気中のH2S,CH3SH(口臭)を測定
し、測定値が比較的高かった被験者12名から歯肉縁下
歯垢検体を採取し、それぞれを0.5mlの生理食塩水
に懸濁させた。口臭菌検査薬としてS−(p−ニトロフ
ェニル)−L−システインを用い、実験1と同様にして
菌の代謝活性を比較した。この場合、S−(p−ニトロ
フェニル)−L−システインが代謝してS−(p−ニト
ロフェニル)メルカプタンが生成するので、反応液中の
S−(p−ニトロフェニル)メルカプタンの吸光度を波
長405nmで測定し、これと呼気中のH2S,CH3
SHの濃度(VSC)との関係を調べた。結果を図1に
示す。
[Example 1] Using gas chromatography, H2S and CH3SH (halitosis) in the exhaled breath of subjects were measured, and subgingival plaque samples were collected from 12 subjects whose measured values were relatively high. was suspended in 0.5 ml of physiological saline. S-(p-nitrophenyl)-L-cysteine was used as a test agent for bad breath bacteria, and the metabolic activities of bacteria were compared in the same manner as in Experiment 1. In this case, S-(p-nitrophenyl)-L-cysteine is metabolized to produce S-(p-nitrophenyl) mercaptan, so the absorbance of S-(p-nitrophenyl) mercaptan in the reaction solution is measured at the wavelength Measured at 405 nm, and H2S, CH3 in exhaled breath
The relationship with the SH concentration (VSC) was investigated. The results are shown in Figure 1.

【0020】図1の結果より、呼気中のH2S,CH3
SH濃度とS−(p−ニトロフェニル)−L−システイ
ンを口臭菌検査薬として使用して生成させたS−(p−
ニトロフェニル)メルカプタンの吸光度値とは高い相関
が認められた。
[0020] From the results shown in Figure 1, H2S and CH3 in exhaled breath
SH concentration and S-(p-nitrophenyl)-L-cysteine produced using halitosis bacteria testing agent.
A high correlation was observed with the absorbance value of (nitrophenyl) mercaptan.

【0021】[実施例2]口臭菌検査薬として2,4−
ジニトロフェニル−L−システインを用い、その2mM
溶液を瀘紙に含浸させ、乾燥して試験紙を製造した。次
に、実施例1と同じ被験者歯周ポケットから浸出液0.
01mlを採取し、これを上記試験紙に染み込ませ、3
7℃で5〜30分間放置し、試験紙の色の変化を観察し
た。
[Example 2] 2,4- as a halitosis bacteria test drug
Using dinitrophenyl-L-cysteine, its 2mM
A test paper was prepared by impregnating filter paper with the solution and drying it. Next, exudate from the periodontal pocket of the same subject as in Example 1 was 0.
Collect 01ml and soak it into the above test paper, 3
The test paper was left to stand for 5 to 30 minutes at 7°C, and changes in the color of the test paper were observed.

【0022】この場合、試験紙は当初白色であるが、2
,4−ジニトロフェニル−L−システインが口臭原因菌
で代謝されて2,4−ジニトロフェニルメルカプタンが
生成すると黄色に変色し、その量が多い程黄色が濃くな
るものである。
In this case, the test paper is initially white, but 2
, 4-dinitrophenyl-L-cysteine is metabolized by bacteria that cause bad breath to produce 2,4-dinitrophenyl mercaptan, which turns yellow, and the greater the amount, the darker the yellow becomes.

【0023】結果を図2に示すが、この結果より呼気中
のH2S,CH3SH濃度と試験紙の色の変化は高い相
関が認められた。
The results are shown in FIG. 2, and it was found that there was a high correlation between the concentration of H2S and CH3SH in exhaled breath and the change in color of the test paper.

【0024】[0024]

【発明の効果】本発明の口臭菌検査薬によれば、フゾバ
クテリウム・ヌクリータム等の口臭菌或いは口臭を簡便
、高感度、特異的に検出することができ、歯周疾患の検
査や口臭の検査に有効に用いられる。
[Effects of the Invention] According to the halitosis bacteria test drug of the present invention, halitosis bacteria such as Fusobacterium nucleatum or halitosis can be detected simply, with high sensitivity, and specifically, and is useful for periodontal disease examinations and halitosis examinations. Used effectively.

【図面の簡単な説明】[Brief explanation of the drawing]

【図1】S−(p−ニトロフェニル)メルカプタンの吸
光度と呼気中のH2S,CH3SHの濃度との関係を示
すグラフである。
FIG. 1 is a graph showing the relationship between the absorbance of S-(p-nitrophenyl)mercaptan and the concentrations of H2S and CH3SH in exhaled breath.

【図2】2,4−ジニトロフェニル−L−システイン含
有試験紙の色と呼気中のH2S,CH3SHの濃度との
関係を示すグラフである。
FIG. 2 is a graph showing the relationship between the color of a 2,4-dinitrophenyl-L-cysteine-containing test paper and the concentration of H2S and CH3SH in exhaled breath.

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】  下記式(1)又は(2)      
  Y−S−CH2−CH(NH2)−COOH   
       …(1)        Y−S−CH
2−CH2−CH(NH2)−COOH  …(2)(
但し、Yは口臭菌により代謝されて生成するY−SHの
量を可視部、紫外部、赤外部又は螢光で測定可能にする
官能基を示す。)で表されるL−システイン又はL−メ
チオニンの誘導体又はその塩からなる口臭菌検査薬。
[Claim 1] The following formula (1) or (2)
Y-S-CH2-CH(NH2)-COOH
...(1) Y-S-CH
2-CH2-CH(NH2)-COOH...(2)(
However, Y represents a functional group that makes it possible to measure the amount of Y-SH metabolized by halitosis bacteria using visible light, ultraviolet light, infrared light, or fluorescence. ) A halitosis bacteria testing agent comprising an L-cysteine or L-methionine derivative or a salt thereof.
JP3089674A 1991-03-28 1991-03-28 Halitosis bacterium-examining chemical Pending JPH04299998A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3089674A JPH04299998A (en) 1991-03-28 1991-03-28 Halitosis bacterium-examining chemical

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3089674A JPH04299998A (en) 1991-03-28 1991-03-28 Halitosis bacterium-examining chemical

Publications (1)

Publication Number Publication Date
JPH04299998A true JPH04299998A (en) 1992-10-23

Family

ID=13977300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3089674A Pending JPH04299998A (en) 1991-03-28 1991-03-28 Halitosis bacterium-examining chemical

Country Status (1)

Country Link
JP (1) JPH04299998A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19827417A1 (en) * 1998-06-19 1999-12-23 Hahn Rainer New material for differentially modifying the optical activities of different cells comprises a mixture of a base material and a modification material
DE19926728A1 (en) * 1999-06-11 2000-12-14 Espe Dental Ag Deformable, hardenable or film-forming carrier containing intraoral diagnostic additives, useful for the simultaneous detection of multiple oral conditions
US7147471B2 (en) 2000-12-08 2006-12-12 3M Espe Ag Use of moulding compounds for producing treatment devices
US8620451B2 (en) 2006-02-06 2013-12-31 Syneron Beauty Inc. Therapy device and system and method for reducing harmful exposure to electromagnetic radiation
US8900231B2 (en) 2004-09-01 2014-12-02 Syneron Medical Ltd Method and system for invasive skin treatment
US8936593B2 (en) 2008-01-24 2015-01-20 Syneron Medical Ltd. Device, apparatus, and method of adipose tissue treatment
US9084587B2 (en) 2009-12-06 2015-07-21 Syneron Medical Ltd Method and apparatus for personal skin treatment
US9271793B2 (en) 2008-09-21 2016-03-01 Syneron Medical Ltd. Method and apparatus for personal skin treatment
US9278230B2 (en) 2009-02-25 2016-03-08 Syneron Medical Ltd Electrical skin rejuvenation
US9295858B2 (en) 2008-07-16 2016-03-29 Syneron Medical, Ltd Applicator for skin treatment with automatic regulation of skin protrusion magnitude
US9314293B2 (en) 2008-07-16 2016-04-19 Syneron Medical Ltd RF electrode for aesthetic and body shaping devices and method of using same
US9504826B2 (en) 2009-02-18 2016-11-29 Syneron Medical Ltd Skin treatment apparatus for personal use and method for using same

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19827417A1 (en) * 1998-06-19 1999-12-23 Hahn Rainer New material for differentially modifying the optical activities of different cells comprises a mixture of a base material and a modification material
US6699040B1 (en) 1998-06-19 2004-03-02 Karl Storz Gmbh & Co., Kg Material for differently modifying the optical properties of different cells
DE19827417B4 (en) * 1998-06-19 2004-10-28 Hahn, Rainer, Dr.Med.Dent. Material for different modification of the optical properties of different cells
US6860879B2 (en) 1998-06-19 2005-03-01 Karl Storz Gmbh & Co. Kg Use of 5-aminolevulinic acid or a derivate thereof for photodynamic diagnosis and/or photodynamic therapy
DE19926728A1 (en) * 1999-06-11 2000-12-14 Espe Dental Ag Deformable, hardenable or film-forming carrier containing intraoral diagnostic additives, useful for the simultaneous detection of multiple oral conditions
DE19926728B4 (en) * 1999-06-11 2011-08-18 3M Espe Ag, 82229 Use of carrier materials and diagnostically useful additives in imaging methods for intraoral diagnostic purposes
US7147471B2 (en) 2000-12-08 2006-12-12 3M Espe Ag Use of moulding compounds for producing treatment devices
US8900231B2 (en) 2004-09-01 2014-12-02 Syneron Medical Ltd Method and system for invasive skin treatment
US8906015B2 (en) 2004-09-01 2014-12-09 Syneron Medical, Ltd Method and system for invasive skin treatment
US8620451B2 (en) 2006-02-06 2013-12-31 Syneron Beauty Inc. Therapy device and system and method for reducing harmful exposure to electromagnetic radiation
US8936593B2 (en) 2008-01-24 2015-01-20 Syneron Medical Ltd. Device, apparatus, and method of adipose tissue treatment
US9295858B2 (en) 2008-07-16 2016-03-29 Syneron Medical, Ltd Applicator for skin treatment with automatic regulation of skin protrusion magnitude
US9314293B2 (en) 2008-07-16 2016-04-19 Syneron Medical Ltd RF electrode for aesthetic and body shaping devices and method of using same
US9271793B2 (en) 2008-09-21 2016-03-01 Syneron Medical Ltd. Method and apparatus for personal skin treatment
US9504826B2 (en) 2009-02-18 2016-11-29 Syneron Medical Ltd Skin treatment apparatus for personal use and method for using same
US9278230B2 (en) 2009-02-25 2016-03-08 Syneron Medical Ltd Electrical skin rejuvenation
US9084587B2 (en) 2009-12-06 2015-07-21 Syneron Medical Ltd Method and apparatus for personal skin treatment

Similar Documents

Publication Publication Date Title
Seiler Use of the dansyl reaction in biochemical analysis
JPH04299998A (en) Halitosis bacterium-examining chemical
Rubinstein et al. The colorimetric estimation of alpha-amino nitrogen in tissue fluids
Piechocka et al. Chromatographic strategies for the determination of aminothiols in human saliva
CN107219283B (en) A kind of method of photic electrochemical gaging glutathione
Akai et al. Salivary urea nitrogen as an index to renal function: a test-strip method.
JP4098475B2 (en) Improvements in homogeneous enzyme assays and H2S detection for vitamin B6
JP2000502989A (en) Improved chemiluminescent 1,2-dioxetanes
KR100976967B1 (en) Total cysteine assay
Drochioiu et al. Highly selective assay of proteins in dilute solutions
JP4286371B2 (en) Determination of homocysteine
JP3164165B2 (en) Calcium determination method
JP3327241B2 (en) Reagents and methods for measuring hydrogen sulfide
JPS63164900A (en) Quantitative determination of creating kinase
JPS6251426B2 (en)
JP3971967B2 (en) Reducing substance quantification method and quantification reagent
JPS6024199A (en) Determination of substance relating to disease
JP2004113129A (en) Liquid for specifying site producing lactic acid on periphery of tooth, and method for using the same
US6340596B1 (en) Reagent composition for measuring hydrogen sulfide and method for measuring hydrogen sulfide
JPH04229198A (en) Examination of periodontosis
JPS61155758A (en) Simultaneous assay of creatinine and creatine and kit therefor
JP4073527B2 (en) Isozyme activity assay
JPS6232344A (en) Method for measuring enzyme activity using reflection optical system
RU2093831C1 (en) Method of determination of creatinine concentration in biological fluids
JPH06339397A (en) Method for removing reductive substance in biological specimen